

Handbook of
Cutaneous Melanoma
A Guide to Diagnosis and Treatment

Handbook of Cutaneous Melanoma

A Guide to Diagnosis and Treatment

Dirk Schadendorf

University Hospital Essen

Department for Dermatology, Venereology and Allergology

Essen

Germany

Co-authors

Corinna Kochs

Elisabeth Livingstone

University Hospital Essen

Department for Dermatology

Essen

Germany



Springer Healthcare

Published by Springer Healthcare Ltd, 236 Gray's Inn Road, London, WC1X 8HB, UK.

www.springerhealthcare.com

© 2013 Springer Healthcare, a part of Springer Science+Business Media.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder.

British Library Cataloguing-in-Publication Data.

A catalogue record for this book is available from the British Library.

ISBN 978-1-908517-97-5

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher nor the authors can be held responsible for errors or for any consequences arising from the use of the information contained herein. Any product mentioned in this publication should be used in accordance with the prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

Project editor: Alla Zarifyan and Tess Salazar

Designer: Joe Harvey

Artworker: Sissan Mollerfors

Production: Marina Maher

Printed in Great Britain by Latimer Trend

Contents

Biographies	vii
Abbreviations	ix
1 Introduction to cutaneous melanoma	1
Epidemiology: incidence and mortality	1
Pathogenesis	3
Prevention and screening	9
References	10
2 Clinical features and classification	13
Subtypes of melanoma	13
American Joint Committee on Cancer staging and classification	17
Prognostic factors and course of disease	17
References	26
3 Diagnosis, staging, and follow-up	29
Initial diagnosis	29
Sentinel lymph node biopsy	36
Diagnostic investigations	42
Follow-up	47
References	48
4 Treatment of primary tumor and locoregional disease	53
Initial treatment of the primary tumor	53
Adjuvant therapy after excision of the primary tumor	58
Treatment of locoregional metastases	62
References	74
5 Treatment of distant and irresectable metastatic disease	79
Surgical therapy of distant metastases	79
Radiotherapy of distant metastases	82
Treatment of metastases in special localizations	85

Systemic treatment	88
References	101
6 Emerging therapies and combination approaches	105
MEK inhibitors	105
Combination of BRAF and MEK inhibitors	106
Combination of vemurafenib and ipilimumab	106
PD-1 and PD-L1 antibodies	107
Further clinical trials	109
References	109

Biographies

Dirk Schadendorf, MD, is the Director of the Department of Dermatology at the University Hospital Essen, Germany. He attended medical school at the University Hospital, Hamburg, Germany, and has been licensed to practice medicine since 1986. In 1987, Professor Schadendorf went to Memorial Sloan-Kettering Cancer Center in New York, USA for 2 years, where he obtained a post-doctorate in tumor immunology. He spent 6 years at the Department of Dermatology at University Hospital Rudolf Virchow in Berlin, where he became board certified for dermatology and venereology and was Assistant Professor for Dermatology. Since 1995, Professor Schadendorf has also received board certification for allergology, quality management, medicamentous tumor therapy, and palliative medicine. After becoming a Heisenberg Scholar in 1997, he was made Associate Professor for Dermato-Oncology at Mannheim University Hospital, Medical Faculty of the University of Heidelberg, and Head of the Skin Cancer Unit at the German Cancer Research Center, Heidelberg, Germany. In his current role as the Director of the Department of Dermatology at University Hospital Essen, Professor Schadendorf is currently involved in 31 clinical studies. He is the current president of the German DeCOG (Dermatologic Cooperative Oncology Group) and chair-elect of the well-known EORTC Melanoma Group. He has a strong focus on translational research and has published more than 300 peer-reviewed papers.

Co-authors

Corinna Kochs, MD, is a resident at the Department of Dermatology, University Hospital Essen, Germany. She studied medicine at the Université Catholique de Louvain, Brussels, Belgium and at the Westfälische Wilhelms University, Münster, Germany. From 2011–2013, she was involved in the development of the German Melanoma Guideline 2013, published by the German Guideline Program in Oncology, where her main responsibilities were the project coordination and methodology. It is the first German Melanoma Guideline that contains evidence as well as GCP (good clinical

practice)-based recommendations on diagnosis, therapy, and follow-up of cutaneous melanoma.

Elisabeth Livingstone, MD, is Attending Physician at the Department of Dermatology, University Hospital Essen, Germany. She studied medicine at Christian-Albrechts University, Kiel, Germany, where she also started her training in dermatology. Her main clinical and research activities are in the field of dermatooncology and cutaneous adverse events of new oncological substances. As sub-investigator, she has been involved in several phase II–III trials for melanoma and basal cell carcinoma.

Abbreviations

AJCC	American Joint Committee of Cancer
APC	antigen-presenting cell
CGH	comparative genomic hybridization
CT	computer tomography
CTLA-4	cytotoxic T-lymphocytic antigen-4
EMA	European Medicines Agency
FDA	US Food and Drug Administration
GM-CSF	granulocyte-macrophage colony-stimulating factor
HDAC	histone deacetylase
ICD-O-3	International Classification of Diseases for Oncology, 3rd edition
IFN	interferon
IHC	immunohistochemistry
IL-2	interleukin-2
LDH	lactate dehydrogenase
MHC	major histocompatibility complex
MRI	magnetic resonance imaging
NICE	National Institute for Health and Care Excellence
NOS	not otherwise specified
PD-1	programmed cell death-1
PET	positron emission tomography
RANKL	receptor activator of nuclear factor kappa-B ligand
SCREEN	Skin Cancer Research to Provide Evidence for Effectiveness of Screening in Northern Germany
SPECT	single photon emission computed tomography
T-VEC	talimogene laherparepvec
TA-99	tyrosinase-related protein antibody
TCR	T-cell receptor
TNF-α	tumor necrosis factor alpha
TNM	T, tumor, N, nodes, M, metastases
TRP-1	tyrosinase-related protein-1

UV	ultraviolet
wb	whole-body
WHO	World Health Organization